Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.jhep.2013.08.020
Title: Reduction of HBV replication prolongs the early immunological response to IFNα therapy
Authors: Tan, A.T.
Hoang, L.T.
Chin, D.
Rasmussen, E.
Lopatin, U.
Hart, S.
Bitter, H.
Chu, T.
Gruenbaum, L.
Ravindran, P.
Zhong, H.
Gane, E.
Lim, S.G. 
Chow, W.C.
Chen, P.-J.
Petric, R.
Bertoletti, A. 
Hibberd, M.L.
Keywords: Chronic HBV
PegIFNa
Tenofovir
Issue Date: Jan-2014
Citation: Tan, A.T., Hoang, L.T., Chin, D., Rasmussen, E., Lopatin, U., Hart, S., Bitter, H., Chu, T., Gruenbaum, L., Ravindran, P., Zhong, H., Gane, E., Lim, S.G., Chow, W.C., Chen, P.-J., Petric, R., Bertoletti, A., Hibberd, M.L. (2014-01). Reduction of HBV replication prolongs the early immunological response to IFNα therapy. Journal of Hepatology 60 (1) : 54-61. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jhep.2013.08.020
Abstract: Background & Aims The interaction between HBV replication and immune modulatory effects mediated by IFNα therapy is not well understood. We characterized the impact of HBV DNA replication on the early IFNα-induced immunomodulatory mechanisms. Methods We interrogated the transcriptional, serum cytokine/chemokine and cellular immune profiles of 28 patients with HBeAg+ chronic HBV infection (CHB) randomly assigned to one of 4 treatment cohorts (untreated n = 5, weekly dosing of 360 μg Pegasys® [PegIFNα] n = 11, daily dose of 300 mg Viread® [tenofovir disoproxil fumarate, TDF] n = 6, or a combination of both n = 6). Samples were characterized at multiple early time points through day 14 of therapy, after which all patients were given standard of care (180 μg Pegasys® injected subcutaneously, weekly). Results PegIFNα induced a distinct and rapid up-regulation of IFN signaling pathway that coincided with increase detection of distinct serum cytokines/chemokines (IL-15, IL-6, and CXCL-10) and the up-regulation of the frequency of proliferating NK and activated total CD8+ T cells. IFNα treatment alone did not result in rapid decay of HBV replication and was not able to restore the defective HBV-specific T cell response present in CHB patients. In addition, the IFNα immune-stimulatory effects diminished after the first dose, but this refractory effect was reduced in patients where HBV replication was simultaneously inhibited with TDF. Conclusions We present here the first comprehensive description of the early effects of IFNα treatment on immune and viral biomarkers in HBeAg+ CHB patients. Our results show that PegIFNα-induced innate immune activation directly benefits from the suppression of HBV replication. © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Source Title: Journal of Hepatology
URI: http://scholarbank.nus.edu.sg/handle/10635/126846
ISSN: 01688278
DOI: 10.1016/j.jhep.2013.08.020
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

47
checked on Sep 12, 2019

WEB OF SCIENCETM
Citations

44
checked on Sep 12, 2019

Page view(s)

26
checked on Sep 6, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.